ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

Role of Pharmacogenomics in Optimising Drug Therapy: A Review

Palak[1]; Akanksha Sharma[2*]; Sanjiv Duggal[3]

[1,2,3]Department of Pharmacy, Global College of Pharmacy Kahanpur Khuhi, Anandpur Sahib, India

Corresponding Author: Akanksha Sharma[*]

Publication Date: 2026/05/11

Abstract: Pharmacogenomics is an emerging field that studies how genetic variations influence individual responses to drugs, with the aim of optimizing therapeutic efficacy and minimizing adverse drug reactions. This review provides a comprehensive overview of pharmacogenomics, beginning with its fundamental concepts and historical background, followed by an exploration of genetic factors involved in drug metabolism. It highlights the role of genetic polymorphisms in determining variability in drug response, including differences in pharmacokinetics and pharmacodynamics among individuals. The importance of pharmacogenomic testing, including genotyping and sequencing techniques, is discussed in the context of personalized medicine. Furthermore, the review examines the clinical applications of pharmacogenomics in various fields such as oncology, cardiovascular diseases, psychiatry, and infectious diseases, along with key examples of pharmacogenomic drugs like warfarin, clopidogrel, and abacavir. The advantages of pharmacogenomics, including improved drug safety and efficacy, are outlined alongside current limitations such as ethical concerns, high costs, and technical challenges. Finally, future perspectives focusing on advancements in genomic technologies, artificial intelligence, and wider clinical implementation are discussed. Overall, pharmacogenomics represents a crucial step toward precision medicine, offering the potential to revolutionize healthcare by enabling individualized drug therapy.

Keywords: *Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Genetic Polymorphism.*

How to Cite: Palak; Akanksha Sharma; Sanjiv Duggal (2026) Role of Pharmacogenomics in Optimising Drug Therapy: A Review. *International Journal of Innovative Science and Research Technology*, 11(4), 4014-4024. https://doi.org/10.38124/ijisrt/26apr1693

I. INTRODUCTION

➢ *Overview of Pharmacogenomics*

Pharmacogenomics, which uses a person's genetic information to customize drug selection, dosage, and regimen, is crucial to the optimization of pharmacological therapy. Proteomics, metabolomics, and other "omics" sciences are used in pharmacogenomics, an expansion of pharmacogenetics. This offers an integrated approach to the field of personalized medicine in a number of treatment domains, such as rare genetic illnesses, cardiovascular medicine, cancer therapy, and psychiatry [1][3][4][5].As biomarkers in drug therapy, genetic differences in drug metabolism enzymes (such CYP2C19 and CYP2D6), drug transporters (like SLCO1B1), and drug receptors are crucial.[4] [7] Although there are issues with clinician knowledge, prices, the regulatory environment, and validation in various populations, pharmacogenomic testing is becoming more widely used in clinical practice and electronic health records for individualized treatment [1][2][4]. Pharmacogenomics has demonstrated encouraging outcomes regarding therapeutic efficacy and toxicity in cardiovascular and cancer therapy, resulting in safer and more precise medication regimes [3][6]. As a result, pharmacogenomics is a crucial component of precision medicine and holds the potential to transform medication therapy by using genetic information to improve patient outcomes [1][4][8].

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693



Fig 1 Pharmacogenomics and Drug Response in Individuals with Different Genotype [14]

➢ *Pharmacogenomics' Development and History:*



Fig 2 History and Development of Pharmacogenomics from Early Observations to Modern Personalized Medicine [2][9][12]

The discovery that individual pharmacological reactions are influenced by genetic characteristics led to the development of pharmacogenomics, formerly known as pharmacogenetics, in the 1950s. Single-gene changes impacting drug metabolism, including cytochrome P450 enzymes, were the focus of early research. However, this has subsequently grown to incorporate multi-gene and genome-wide techniques combining various "omics" data (genomics, transcriptomics, proteomics) [2][9][16]. Over the past 50 years, advances in molecular technologies and DNA sequencing have significantly improved our understanding of genetic variability and how it affects the safety and efficacy of drugs, resulting in verified clinical applications and integration into electronic health records [2][10]. Despite advancements, complicated gene interactions, uncommon variations, testing method uniformity, and knowledge shortages in the healthcare workforce continue to pose obstacles to practical application [10] [11] [13]. In order to maximize medication therapy customized to each patient's unique genetic profile, the field is moving toward comprehensive personalized medicine strategies that use biobanks, artificial intelligence, and large-scale data integration [1][9]. In order to fully achieve the benefits of customized pharmacotherapy, future initiatives include creating regulatory frameworks, increasing access to pharmacogenomic testing globally, and improving healthcare practitioner education [2][13][15].



Fig 3 Flowchart Showing Evolution of Pharmacogenomics

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

➢ *Background of Pharmacogenomics:*



Fig 4 Biological Mechanisms Involved in Pharmacogenomics.[1]

- *Explanation:*

To comprehend medication response variability, pharmacogenomics combines several biological layers, such as transcriptomics, proteomics, metabolomics, and genomics. Single nucleotide polymorphisms (SNPs) and other genetic changes can affect receptor activation, drug transport, and drug metabolism. Researchers can forecast therapy results and enhance medication safety and effectiveness by examining these pathways.

Pharmacogenomics is the study of how individual pharmacological responses are influenced by genetic diversity, with the goal of optimizing treatment efficacy and minimizing side effects by customizing therapies to an individual's genetic composition [1][2]. A more thorough understanding of drug response variability has been made possible by the field's expansion from pharmacogenetics, which concentrated on single gene-drug interactions in the 1950s, to several "omics" technologies, including proteomics, metabolomics, and genomics [1][9]. Pharmacogenomics has grown rapidly due to advancements in molecular technology and DNA sequencing, which have resulted in verified clinical applications and integration into electronic health records for customized treatment [2][10]. Despite these developments, complicated gene interactions, ethnic variation in genetic variants, healthcare professionals' lack of expertise, and the requirement for standardized testing and reporting continue to pose obstacles to clinical application [8][13][17]. By identifying genetic targets that increase the success rates of clinical development, pharmacogenomics also contributes to drug discovery [13]. To fully exploit the benefits of personalized pharmacotherapy, future developments will focus on machine learning techniques, large-scale biobank data integration, multi-gene and polygenic models, and wider clinical use [7][9][10].

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693



Fig 5 Workflow of Pharmacogenomics-Guided Personalized Drug Therapy

- *Factors Influencing Drug Response*: Drug Response depends on



Fig 6 Major Biological and Environmental Factors Influencing Pharmacogenomics Drug Response.

➢ *Comparison between Pharmacogenetics and Pharmacogenomics:*

The related disciplines of pharmacogenetics and pharmacogenomics investigate how genetic diversity affects a person's reaction to medications. Traditionally, pharmacogenetics has concentrated on how single gene variants, especially those that encode drug-metabolizing enzymes, affect drug metabolism and response. Pharmacogenomics, on the other hand, adopts a more comprehensive strategy by investigating how the entire

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

genome or a number of genes affect medication response, including pharmacokinetics and pharmacodynamics. Pharmacogenomics combines genome-wide data with other "omics" techniques to better comprehend intricate drug response patterns thanks to advancements in genomic technologies. Pharmacogenomics is a more comprehensive framework that supports the development of personalized medicine by customizing pharmacological therapy based on an individual's genetic profile, even if the line between the two concepts is sometimes obscured [1][2][9][12].

Table 1 Comparison between Pharmacogenetics and Pharmacogenomics

Feature	Pharmacogenetics	Pharmacogenomics
Scope	Study of single gene effects on drug response	Study of entire genome effects on drug response
Approach	Monogenic gene–drug interactions	Genome-wide analysis
Focus	Drug metabolism genes	Multiple genes, pathways, and systems
Data Type	Individual gene polymorphisms	Genomic and multi-omics data
Application	Understanding specific drug responses	Personalized medicine and precision therapy



Fig 7 Comparison between Pharmacogenetics and Pharmacogenomics in Terms of Scope, Methodology, and Applications in Personalized Medicine [1][12][16]

II. GENETIC VARIABILITY AND DRUG RESPONSE

➢ *Genetic Polymorphisms:*

According to Cavalli-Sforza and Bodmer, genetic polymorphism is defined as the presence of two or more alleles at a single locus in the same population, each with a significant frequency; 1% is usually considered the minimum frequency [18]. One of a gene's different forms at a particular locus on a homologous chromosome is called an allele. In the general population, the many polymorphism forms (alleles) are more frequently seen than mutations. The single-nucleotide polymorphism (SNP) is the most prevalent variant in the human genome [19].

➢ *Single Nucleotide Polymorphisms (SNPs):*

Are the most prevalent kind of genetic variation seen in the human genome; they involve a single nucleotide base change at a particular location. They affect gene expression, protein function, and disease susceptibility and can be found in coding regions (exons), noncoding regions (introns), promoters, and untranslated regions. They occur around once every 1,000 base pairs [20][21][22]. SNPs can impact phenotypic and complex diseases including cancer, diabetes, and psychiatric disorders by affecting mRNA stability, localization, and epigenetic control. They can be synonymous (silent) or nonsynonymous (changing amino acids) [20][23]. By assisting in the prediction of individual treatment responses and illness risks, these polymorphisms are crucial molecular markers for genetic association research, forensic identification, and personalized medicine [22]. The clinical value of SNPs has been enhanced by advances in high-throughput sequencing and machine learning, which have improved the accuracy of SNP identification and the classification of pathogenic vs benign variants [23][24]. Furthermore, biosensor technologies are being developed to facilitate sensitive and quick SNP detection for diagnostic purposes [25].

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

➢ *How Genes Generate Genetic Variation:*

When genes and their products modify DNA sequences, rearrange them, or change how they are expressed, genetic variation results. The raw materials for the evolution of bacteria, plants, animals, and humans are provided by these processes.

➢ *Core Genetic Mechanisms Creating Variation:*

Table 2 Major Molecular Routes by which Genes Generate Variation.

Mechanism	What changes	Typical molecular causes	Citations
Mutation	Individual bases or small indels	Replication errors, DNA damage, imperfect repair	[26][27][28][29]
Recombination (crossing over)	Large DNA segments reshuffled	Programmed meiotic double-strand breaks and repair	[30][31][32][33]
Gene conversion	Short, non-reciprocal tracts replaced	Homologous recombination using a template	[34][35][36][37][38][39]
DNA rearrangements	Duplications, deletions, inversions, transposition	Mobile elements, repeat-mediated recombination	[40][41][42][43]

III. PHARMACOGENOMICS IN OPTIMIZING DRUG THERAPY

➢ *Dose Optimization:*

Finding doses that maximize therapeutic effect while limiting toxicity is the goal of dose optimization in drug development, particularly in cancer. The maximum tolerated dose (MTD) was the emphasis of traditional dose-finding techniques, but this method frequently results in increased toxicity without increasing the effectiveness of targeted medicines and immunotherapies. With the use of quantitative pharmacology, pharmacokinetics, and pharmacodynamics, modern approaches focus on identifying an ideal biological dose through early characterisation of dose-response relationships and randomized dose trials [44][45][46][47]. In order to improve patient outcomes and decrease postmarketing dose changes, the FDA's Project Optimus effort emphasizes the need for a paradigm shift toward more rigorous dose optimization and encourages randomized study of several doses prior to registration trials [48][49][50]. 3.2. Personalised techniques integrate preclinical data, clinical measurements, and modelling to balance efficacy and safety, taking into account drug classes and mechanisms of action to guide dose selection [46][51]. Despite advancements, there are still obstacles to widespread application of these strategies because of the underutilization of creative trial designs and the intricacy of early-phase research. However, continuous attempts are made to standardize and enhance dosage optimization procedures in oncology medication development [46][52].

➢ *Reduction of Adverse Drug Reactions:*

Adverse drug reactions (ADRs) in older persons have been demonstrated to be significantly reduced by interventions, especially pharmacist-led programs that can reduce any ADRs by around 19–35% and major ADRs by up to 32–36% [53, 54]. These interventions, which are used in a variety of healthcare settings such hospitals, outpatient clinics, and community pharmacies, frequently involve medication reviews, patient counselling, and multidisciplinary teamwork [53][55]. The need for thorough geriatric assessments and customized medication management is highlighted by age-related factors that raise the risk of adverse drug reactions (ADRs) in older populations, such as polypharmacy, changes in drug metabolism, and frailty [56][57]. By combining data from clinical trials and real-world monitoring, digital technologies, like as machine learning algorithms and electronic health records, are rapidly being used to enhance ADR detection, pharmacovigilance, and preventive efforts [58]. Despite these developments, some research shows that treatments have little effect on more general health outcomes like hospitalization or mortality, suggesting the need for fresh ideas and improved implementation techniques [59, 60, 61]. In order to enhance early identification and clinical decision-making to prevent adverse drug reactions (ADDRs), tools like the ADR Profile have been proven to accurately identify medication-related harms in primary care [60][61][62].

➢ *Clinical Applications*

Table 3 Clinical Applications of Pharmacogenomics:

Area	Main gene–drug examples & use	Citations
Oncology	Germline: DPYD–fluoropyrimidines, TPMT/NUDT15–thiopurines, UGT1A1–irinotecan for dose reduction/toxicity avoidance; Somatic: EGFR, ALK, KRAS/NRAS, BRAF, BRCA1/2 guide targeted and PARP inhibitor use	[63][64]
Cardiovascular diseases	CYP2C19–clopidogrel (poor metabolizers → prasugrel/ticagrelor); CYP2C9 & VKORC1–warfarin dosing; SLCO1B1–simvastatin myopathy risk; emerging roles for PGx in novel agents (e.g., mavacamten)	[65][66]

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

Psychiatry	CYP2D6 & CYP2C19 for many antidepressants and antipsychotics (dose/agent selection); HLA-B*15:02/*31:01 for carbamazepine/oxcarbazepine; CYP2C9 & HLA-B for phenytoin; growing large trials (e.g., PSY-PGx)	[67][68]
Infectious diseases	Host: HLA-B*57:01–abacavir hypersensitivity; IL28B variants–interferon/ribavirin response in HCV (historical); Pathogen genome: resistance genes guide antibiotic/antiviral choice	[69]
Pain management	CYP2D6 for codeine, tramadol (avoid ultra-/poor metabolizers); CYP2D6/CYP2B6/ABCB1 for oxycodone, methadone; CYP2C9 for some NSAIDs; OPRM1, COMT, HLA variants under study; PGx-guided opioids may reduce consumption and adverse events	[70][71]

➢ *Pharmacogenomic Testing and Technologies:*

Table 4 Comparison of Main Pharmacogenomic Test Methods

Method/platform	**Typical use in PGx**	**Key pros/cons**
PCR / small arrays	Single-gene or small candidate panels	Fast, cheap; limited variant coverage
SNP arrays / SNV panels	Clinical multi-gene panels	Good for common variants; miss rare/structural
Short-read NGS (targeted, WES, WGS)	Research & emerging clinical PGx	Broad variant detection; interpretation, cost, pipelines challenging
Long-read / TAS-LRS	Complex loci (e.g., CYP2D6, HLA)	Resolves structural variants, phasing; still emerging

➢ *Importance of Pharmacogenomics:*

Pharmacogenomics is significant because it examines how a person's genetic composition affects how they react to drugs. By choosing the appropriate medication and dosage for each patient, it helps optimize drug therapy and replaces the conventional "one-size-fits-all" approach with a more individualized treatment plan [72].



Fig 8 Significance of Pharmacogenomics

IV. CHALLENGES IN CLINICAL IMPLEMENTATION

Clinical implementation of pharmacogenomics (PGx) aims to personalize medicine by improving drug efficacy, safety, and cost-effectiveness, but widespread adoption faces barriers such as limited healthcare provider education, reimbursement challenges, and integration into electronic health records (EHRs) [73][74][76]. Successful clinical programs emphasize building secure IT infrastructure with clinical decision support systems, selecting actionable gene-drug pairs based on expert-curated guidelines like those from CPIC, and involving multidisciplinary teams including hospital leadership, pharmacy committees, laboratories, and clinicians [73][74][77]. Pre-emptive PGx testing in psychiatry has demonstrated significant reductions in adverse drug reactions, hospitalizations, polypharmacy, and treatment costs while improving patient quality of life, supporting its

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

clinical utility [73][78]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) plays a pivotal role by providing evidence-based guidelines that facilitate global adoption and standardization of PGx in clinical practice [77]. Real-world implementations such as the University of Florida's Personalized Medicine Program show feasibility with rapid genotyping turnaround times and high reimbursement rates from payors [81]. Despite progress, challenges remain in expanding PGx education for healthcare providers and patients, securing reimbursement policies, and generating broader evidence for multigene panel testing to fully integrate pharmacogenomics into routine care [73][78][79].

Table 5 Challenges in Clinical Implementation

Challenge Category	Key Issues
Ethical	Privacy concerns, genetic discrimination, informed consent
Economic	High cost of testing, limited reimbursement
Technical	Data interpretation difficulties, lack of standardized tests
Clinical	Limited genomic literacy among healthcare providers
Research	Insufficient data from diverse populations

➢ *Future Perspectives of Pharmacogenomics:*

The future of pharmacogenomics (PGx) is poised to significantly advance personalized medicine by integrating genomic data with other "omics" fields such as epigenetics, metabolomics, and microbiomics, enabling more precise drug selection and dosing tailored to individual patients [82]. Technological progress in DNA sequencing, machine learning, and large-scale biobanks will enhance the discovery of novel genetic markers and polygenic models that better explain interindividual variability in drug response beyond single gene variants [9][83][84]. Clinical implementation is expected to expand from targeted genotyping toward sequencing-based approaches that capture rare variants and complex genetic interactions, supported by improved standardization and harmonization efforts across laboratories [10]. Despite these advances, challenges remain including knowledge gaps among healthcare providers, regulatory and ethical considerations, data privacy concerns, and ensuring equitable access to PGx-guided therapies worldwide [1][13][82]. In psychiatry, emerging multi-omics strategies combined with pharmacogenomics hold promise for overcoming current limitations in treatment response prediction and personalizing psychiatric care [85][86]. Overall, pharmacogenomics is anticipated to evolve into a cornerstone of precision medicine by refining therapeutic strategies to maximize efficacy and minimize adverse effects through comprehensive integration of genetic and environmental factors [1][13][83].

V. CONCLUSION

Drug therapy is being transformed by pharmacogenomics, which makes it possible to customize therapies based on a patient's genetic makeup. This strategy contributes to safer and more effective patient care by increasing medication efficacy while lowering the possibility of side effects. Ongoing developments in genetic research are making its therapeutic usage easier, but ongoing challenges such high prices, low awareness, and ethical issues. Pharmacogenomics is expected to play a significant role in customized medicine in the years to come, guaranteeing improved therapeutic results and efficient healthcare delivery.

REFERENCES

[1]. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacological reviews. 2023 Jul 1;75(4):789-814.
[2]. Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. InMayo Clinic Proceedings 2017 Nov 1 (Vol. 92, No. 11, pp. 1711-1722). Elsevier.
[3]. Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of internal medicine. 2024 May;295(5):583-98.
[4]. Chandan TR, Patil CD, Kundgir VB, Chaudhari K, Bachhav RL, Bhamare MS, Sonawane SK, Mahajan SK. Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy. Research journal of Pharmacology and Pharmacodynamics. 2025 Oct 1;17(4):311-8.
[5]. Roman YM. Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics. Pharmacogenomics. 2025 Mar 4;26(3-4):121-8.
[6]. Sánchez-Bayona R, Catalán C, Cobos MA, Bergamino M. Pharmacogenomics in solid tumors: A comprehensive review of genetic variability and its clinical implications. Cancers. 2025 Mar 7;17(6):913.
[7]. Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. The AAPS journal. 2017 Nov 27;20(1):4.
[8]. Roden DM, Tyndale RF. Genomic Medicine. Pre-IMIA Yearbook of Medical Informatics. 2014.
[9]. Auwerx C, Sadler MC, Reymond A, Kutalik Z. From pharmacogenetics to pharmaco-omics: Milestones and future directions. Human Genetics and Genomics Advances. 2022 Apr 14;3(2).
[10]. Moyer AM, Black JL. Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities. Annals of Laboratory Medicine. 2025 Apr 2;45(3):247-58.
[11]. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discovery Today. 2011 Oct 1;16(19-20):852-61.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

[12]. Pirmohamed M. Pharmacogenetics and pharmacogenomics. British journal of clinical pharmacology. 2001 Oct;52(4):345.
[13]. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023 Jun;24(6):350-62.
[14]. Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM. Pharmacogenomics as a tool to limit acute and long-term adverse effects of chemotherapeutics: an update in pediatric oncology. Frontiers in Pharmacology. 2020 Aug 5;11:1184.
[15]. Kryukov AV, Zhiryakova AS, Shevchuk YV, Matveev AV, Vechorko VI, Averkov OV, Glagolev SV, Temirbulatov II, Mirzaev KB, Denisenko NP, Abdullaev SP. Safety of pharmacotherapy in COVID-19 patients: A literature review. Safety and risk of pharmacotherapy. 2022 Dec 29;10(4):326-44.
[16]. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet.. 2006 Sep 22;7(1):223-45.
[17]. White C, Scott R, Paul CL, Ackland SP. Pharmacogenomics in the era of personalised medicine. The Medical Journal of Australia. 2022 Oct 18;217(10):510.
[18]. Ingelman-Sundberg M, Nebert DW, Lauschke VM. Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. Human Genomics. 2023 Nov 24;17(1):105.
[19]. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu. Rev. Med. 2005 Feb 18;56(1):303-20.
[20]. Komar AA. Single nucleotide polymorphisms. Methods in Molecular Biology. 2009;578(10):978.
[21]. Deng NA, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 2017 Nov 7;8(66):110635.
[22]. Sukhumsirichart W. Polymorphisms. InGenetic diversity and disease susceptibility 2018 Oct 17. IntechOpen..
[23]. Azizzadeh-Roodpish S, Garzon MH, Mainali S. Classifying single nucleotide polymorphisms in humans. Molecular Genetics and Genomics. 2021 Sep;296(5):1161-73.
[24]. Yatskou MM, Sarnatski DD, Skakun VV, Grinev VV. Software complex for simulation modelling of single nucleotide genetic polymorphism sites. InInformatics 2025 Jul 10 (Vol. 22, No. 2, pp. 81-94).
[25]. Wu K, Kong F, Zhang J, Tang Y, Chen Y, Chao L, Nie L, Huang Z. Recent progress in single-nucleotide polymorphism biosensors. Biosensors. 2023 Sep 1;13(9):864.
[26]. Arber W. Genetic variation: molecular mechanisms and impact on microbial evolution. FEMS microbiology reviews. 2000 Jan 1;24(1):1-7.
[27]. Eggertsson H. GraphTyper: A pangenome method for identifyingsequence variants at a population scale.
[28]. Domingo, E. (2019). Molecular basis of genetic variation of viruses. *Virus as Populations*, 35 - 71.
[29]. Herrick AL, Kiser JN, White SN, Neibergs HL. Genomic Regions Associated with Respiratory Disease in Holstein Calves in the Southern United States. Genes. 2025 Jun 26;16(7):741.
[30]. Morrell, P., Toleno, D., Lundy, K., & Clegg, M. (2006). Estimating the Contribution of Mutation, Recombination and Gene Conversion in the Generation of Haplotypic Diversity. *Genetics*, 173, 1705 - 1723.
[31]. Morrell PL, Toleno DM, Lundy KE, Clegg MT. Estimating the contribution of mutation, recombination and gene conversion in the generation of haplotypic diversity. Genetics. 2006 Jul 1;173(3):1705-23.
[32]. Gardiner LJ, Wingen LU, Bailey P, Joynson R, Brabbs T, Wright J, Higgins JD, Hall N, Griffiths S, Clavijo BJ, Hall A. Analysis of the recombination landscape of hexaploid bread wheat reveals genes controlling recombination and gene conversion frequency. Genome Biology. 2019 Apr 15;20(1):69.
[33]. Arbeithuber B, Betancourt AJ, Ebner T, Tiemann-Boege I. Crossovers are associated with mutation and biased gene conversion at recombination hotspots. Proceedings of the National Academy of Sciences. 2015 Feb 17;112(7):2109-14.
[34]. Stritt C, Reitsma M, Marin AM, Goig G, Dötsch A, Borrell S, Beisel C, Comas I, Brites D, Gagneux S. Gene conversion and duplication contribute to genetic variation in an outbreak of Mycobacterium tuberculosis. Microbial Genomics. 2025 May 1;11(5):001396.
[35]. Morrell PL, Toleno DM, Lundy KE, Clegg MT. Estimating the contribution of mutation, recombination and gene conversion in the generation of haplotypic diversity. Genetics. 2006 Jul 1;173(3):1705-23.
[36]. Chen JM, Cooper DN, Chuzhanova N, Férec C, Patrinos GP. Gene conversion: mechanisms, evolution and human disease. Nature Reviews Genetics. 2007 Oct;8(10):762-75.
[37]. Kurosawa K, Ohta K. Genetic diversification by somatic gene conversion. Genes. 2011 Jan 10;2(1):48-58.
[38]. Daugherty MD, Zanders SE. Gene conversion generates evolutionary novelty that fuels genetic conflicts. Current Opinion in Genetics & Development. 2019 Oct 1;58:49-54.
[39]. Link VM, Duttke SH, Chun HB, Holtman IR, Westin E, Hoeksema MA, Abe Y, Skola D, Romanoski CE, Tao J, Fonseca GJ. Analysis of genetically diverse macrophages reveals local and domain-wide mechanisms that control transcription factor binding and function. Cell. 2018 Jun 14;173(7):1796-809.
[40]. Stritt C, Reitsma M, Marin AM, Goig G, Dötsch A, Borrell S, Beisel C, Comas I, Brites D, Gagneux S. Gene conversion and duplication contribute to genetic variation in an outbreak of Mycobacterium tuberculosis. Microbial Genomics. 2025 May 1;11(5):001396.
[41]. Frías-Lasserre D, Villagra CA. The importance of ncRNAs as epigenetic mechanisms in phenotypic variation and organic evolution. Frontiers in Microbiology. 2017 Dec 22;8:2483.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

[42]. Lin RC, Ferreira BT, Yuan YW. The molecular basis of phenotypic evolution: beyond the usual suspects. Trends in Genetics. 2024 Aug 1;40(8):668-80.
[43]. Chen ZJ. Genetic and epigenetic mechanisms for gene expression and phenotypic variation in plant polyploids. Annu. Rev. Plant Biol.. 2007 Jun 2;58:377-406.
[44]. Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, Hudson R, Sridhara R, Ison G, Amiri-Kordestani L, Tang S. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. Journal of Clinical Oncology. 2022 Oct 20;40(30):3489-500.
[45]. Glasmacher A, Garralda E, Gwaltney C, Rupalla K, Li C, Weber H. Dose optimization in cancer drug development: review and outcome of a multi-stakeholder workshop. European Journal of Cancer. 2025 Aug 26;226:115593.
[46]. Zhu J, Schroeder A, Frank S, Boetsch C, Jamois C, Kassir N, Korfi K, Punnoose E, Vaze A, Trask P, Gosai P. Oncology dose optimization: tailored approaches to different molecular classes. Clinical Pharmacology & Therapeutics. 2025 Jul;118(1):74-9.
[47]. Papachristos A, Patel J, Vasileiou M, Patrinos GP. Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics. Cancers. 2023 Jun 18;15(12):3233.
[48]. Rahman A, Shah M, Shord SS. Dosage optimization: a regulatory perspective for developing oncology drugs. Clinical Pharmacology & Therapeutics. 2024 Sep;116(3):577-91.
[49]. Kitagaki H, Takeda K, Murai K, Maeda H. Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments. Clinical Pharmacology & Therapeutics. 2025 Oct;118(4):823-30.
[50]. Samineni D, Venkatakrishnan K, Othman AA, Pithavala YK, Poondru S, Patel C, Vaddady P, Ankrom W, Ramanujan S, Budha N, Wu M. Dose optimization in oncology drug development: an international consortium for innovation and quality in pharmaceutical development white paper. Clinical Pharmacology & Therapeutics. 2024 Sep;116(3):531-45.
[51]. Dharia N, Zhu J, Schroeder A, Frank S, Boetsch C, Jamois C, Kassir N, Korfi K, Punnoose E, Vaze A, Trask P. Refining oncology dose selection: A framework for tailored dose optimization in the era of targeted and immunotherapies. Cancer Research. 2025 Apr 21;85(8_Supplement_1):2514-.
[52]. Korn EL, Moscow JA, Freidlin B. Dose optimization during drug development: whether and when to optimize. JNCI: Journal of the National Cancer Institute. 2023 May 1;115(5):492-7.
[53]. Gray SL, Perera S, Soverns T, Hanlon JT. Systematic review and meta-analysis of interventions to reduce adverse drug reactions in older adults: an update. Drugs & aging. 2023 Sep 13;40(11):965.
[54]. Gray SL, Hart LA, Perera S, Semla TP, Schmader KE, Hanlon JT. Meta-analysis of interventions to reduce adverse drug reactions in older adults. Journal of the American Geriatrics Society. 2018 Feb;66(2):282-8. - analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults.
[55]. Alabbasi AK, Green MS, Brammli-Greenberg S, Haj MB, Preis M, Schwartz N, Lavon O, Klang S, Cohen S. Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial. JCO Oncology Practice. 2025 Jul:OP-25.
[56]. Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. European geriatric medicine. 2021 Jun;12(3):463-73.
[57]. Wasiullah W, Yadav Y, Vishwakarma M, Soni S. A review article on the unseen risks of medication: understanding the causes and consequences of adverse drug reaction. 2025.
[58]. Litvinova O, Yeung A, Hammerle F, Mickael M, Matin M, Kletečka-Pulker M, Atanasov A, Willschke H. Pharmaceuticals. 2024;17.
[59]. Tecklenborg S, Byrne C, Cahir C, Brown L, Bennett K. Interventions to Reduce Adverse Drug Event-Related Outcomes in Older Adults: A Systematic Review and Meta-analysis: S. Tecklenborg et al. Drugs & Aging. 2020 Feb;37(2):91-8.
[60]. Logan V, Hughes D, Turner A, Carter N, Jordan S. Methods for identifying adverse drug reactions in primary care: A systematic review. Plos one. 2025 Feb 4;20(2):e0317660.
[61]. Logan V, Carter N, Hughes D, Turner A, Jordan S. Reducing Adverse Drug Reactions for Older People in the Community: Evaluating the Validity and Reliability of the ADRe Profile. Journal of Nursing Management. 2025;2025(1):9921349.
[62]. Chourasiya S, Patel P. A review on adverse drug reaction related to medication in health sector: an account of what we have discovered and implemented—pharmacovigilance. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 Nov;398(11):14663-82.
[63]. Sánchez-Bayona R, Catalán C, Cobos MA, Bergamino M. Pharmacogenomics in solid tumors: A comprehensive review of genetic variability and its clinical implications. Cancers. 2025 Mar 7;17(6):913.
[64]. Nafchi HM, Solatzadeh H, Hajimaghsoudi E, Babakhanzadeh E. Personalizing cancer therapy: the role of pharmacogenetics in overcoming drug resistance and toxicity. Molecular Biology Reports. 2025 Dec;52(1):785.
[65]. Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of internal medicine. 2024 May;295(5):583-98.
[66]. Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology. 2021 Sep;18(9):649-65.

ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1693

[67]. Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen LS. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021 Jan;54(01):5-17.

[68]. Van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Frontiers in Psychiatry. 2020 Mar 12; 11:94.

[69]. Hayney MS. Pharmacogenomics and infectious diseases: impact on drug response and applications to disease management. American journal of health-system pharmacy. 2002 Sep 1;59(17):1626-31.

[70]. Jethwa S, Ball M, Langlands K. Pharmacogenomic-guided opioid therapy for pain: a systematic review and meta-analysis of randomised controlled trials. The Pharmacogenomics Journal. 2025 Aug;25(4):20.

[71]. Brandl E, Halford Z, Clark MD, Herndon C. Pharmacogenomics in pain management: a review of relevant gene-drug associations and clinical considerations. Annals of Pharmacotherapy. 2021 Dec;55(12):1486-501.

[72]. Herrick AL, Kiser JN, White SN, Neibergs HL. Genomic Regions Associated with Respiratory Disease in Holstein Calves in the Southern United States. Genes. 2025 Jun 26;16(7):741.

[73]. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. Journal of pharmaceutical sciences. 2017 Sep 1;106(9):2368-79.

[74]. Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Frontiers in pharmacology. 2023 May 18;14:1189976.

[75]. Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, Ferentinos P, Bartsakoulia M, Katsila T, Mitropoulou C, Patrinos GP. Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine. 2024 Mar 1;101.

[76]. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023 Jun;24(6):350-62.

[77]. Caudle KE, Whirl-Carrillo M, Relling MV, Hoffman JM, Donnelly RS, Haidar CE, Bourque MS, Frear S, Gong L, Sangkuhl K, Whaley R. Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacology & Therapeutics. 2025 Dec;118(6):1512-22.

[78]. Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clinical Pharmacology & Therapeutics. 2018 May;103(5):778-86.

[79]. Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Human genomics. 2019 Aug 27;13(1):39.

[80]. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clinical Pharmacology & Therapeutics. 2017 Mar;101(3):341-58.

[81]. Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, Cooper-DeHoff RM. Clinical pharmacogenetics implementation: approaches, successes, and challenges. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2014 Mar (Vol. 166, No. 1, pp. 56-67).

[82]. Shaman JA. The future of pharmacogenomics: integrating epigenetics, nutrigenomics, and beyond. Journal of Personalized Medicine. 2024 Nov 27;14(12):1121.

[83]. Lauschke VM, Zhou Y, Ingelman-Sundberg M. Pharmacogenomics beyond single common genetic variants: the way forward. Annual Review of Pharmacology and Toxicology. 2024 Jan 23;64(1):33-51.

[84]. Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacology & therapeutics. 2019 May 1;197: 122-52.

[85]. Pardiñas AF, Owen MJ, Walters JT. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron. 2021 Dec 15;109(24):3914-29.

[86]. Bousman CA, Al Maruf A, Marques DF, Brown LC, Müller DJ. The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review. Psychological medicine. 2023 Dec;53(16):7983-93.